Oramed Pharmaceuticals (FRA:OJU1) EBITDA Margin %: 0.00% (As of Mar. 2026)


FRA:OJU1 Oramed Pharmaceuticals Inc FRA:OJU1
34 GF Score
Price €3.99
! 5 Warning Signs
View Full Analysis

What is Oramed Pharmaceuticals EBITDA Margin %?

Oramed Pharmaceuticals FRA:OJU1 -4.09% 34 EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus rates FRA:OJU1 with a GF Score™ of 34/100. The stock has 5 warning signs investors should review. Among 939 Biotechnology companies, Oramed Pharmaceuticals ranks worse than 106496.17% on this metric.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Oramed Pharmaceuticals's EBITDA for the three months ended in Mar. 2026 was €-3.14 Mil. Oramed Pharmaceuticals's Revenue for the three months ended in Mar. 2026 was €0.00 Mil. Therefore, Oramed Pharmaceuticals's EBITDA margin for the quarter that ended in Mar. 2026 was 0.00%.

Oramed Pharmaceuticals  (FRA:OJU1) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Oramed Pharmaceuticals EBITDA Margin % Related Terms

Oramed Pharmaceuticals EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for Oramed Pharmaceuticals's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Oramed Pharmaceuticals EBITDA Margin % Chart

Oramed Pharmaceuticals Annual Data
Trend Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Dec22 Dec23 Dec24 Dec25
EBITDA Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -893.12 -1,391.07 546.22 0.00 3,772.25

Oramed Pharmaceuticals Quarterly Data
May21 Aug21 Nov21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -223.51 0.00 0.00 0.00 0.00

FRA:OJU1 vs EQ, HUMA, NBP: EBITDA Margin % Comparison

For the Biotechnology subindustry, Oramed Pharmaceuticals's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Oramed Pharmaceuticals EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oramed Pharmaceuticals's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Oramed Pharmaceuticals's EBITDA Margin % falls into.


FRA:OJU1
34GF Score
Oramed Pharmaceuticals Inc FRA:OJU1
EBITDA Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Oramed Pharmaceuticals EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Oramed Pharmaceuticals's EBITDA Margin % for the fiscal year that ended in Dec. 2025 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=64.43/1.708
=3,772.25 %

Oramed Pharmaceuticals's EBITDA Margin % for the quarter that ended in Mar. 2026 is calculated as

EBITDA Margin %=EBITDA (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-3.139/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of 0.00% mean?
Oramed Pharmaceuticals (FRA:OJU1) has a EBITDA Margin % of 0.00% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Oramed Pharmaceuticals and its competitors. According to the industry distribution chart, Oramed Pharmaceuticals ranks #999999 out of 939 companies in the Biotechnology industry.
Is Oramed Pharmaceuticals' EBITDA Margin % too high?
Oramed Pharmaceuticals' current EBITDA Margin % is 0.00%. Based on the distribution chart, Oramed Pharmaceuticals ranks #999999 out of 939 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Oramed Pharmaceuticals has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Oramed Pharmaceuticals' EBITDA Margin % compare to EQ and HUMA?
According to the Biotechnology industry distribution chart, Oramed Pharmaceuticals ranks #999999 out of 939 companies for EBITDA Margin %. This places Oramed Pharmaceuticals in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Oramed Pharmaceuticals and its competitors. Oramed Pharmaceuticals's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oramed Pharmaceuticals stock overvalued right now?
Oramed Pharmaceuticals (FRA:OJU1) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. Oramed Pharmaceuticals' overall GF Score™ is 34/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Oramed Pharmaceuticals (FRA:OJU1), the current EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Oramed Pharmaceuticals Business Description

Address 1185 Avenue of the Americas, Third Floor, New York, NY, USA, 10036
Oramed Pharmaceuticals Inc is a pharmaceutical company that is engaged in the research and development of pharmaceutical solutions with a technology platform that allows for the oral delivery of therapeutic proteins. The company has developed an oral dosage form intended to withstand the harsh environment of the gastrointestinal tract and effectively deliver active insulin or other proteins. Its product pipeline includes ORMD-0801 for Diabetes, ORMD-0801 for NASH, and ORMD 0901.
34GF Score

Get the complete analysis for FRA:OJU1

EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.99
Price